Paper Review Records
All Paper Review Records
15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
QuBIN: quantum-accelerated discovery of conserved interactions in multi-omics networks
Abdul Mannan Kitab; Yiming Zeng; Qing Ye; Nancy Lan GuoShow moreShow less
1. School of Computing, Binghamton University, Binghamton, USA; 2. Sostos Inc., Morgantown, USAShow moreShow less
Cracking the miRNome: lessons learned and future directions in microRNA CRISPR screening
Iulia A. Grigore; Jonathan Tak-Sum Chow; Leonardo SalmenaShow moreShow less
1. Department of Pharmacology & Toxicology, University of Toronto, Toronto, CanadaShow moreShow less
Polygenic risk for type 2 diabetes modulates gut microbiome associations across metabolic health traits
Lauma Jagare; Ilze Elbere; Maija Rozenberga; Ivars Silamiķelis; Marija Simona Dombrovska; Ivanna Atava; Alvīne Helēna Janševska; Monta Brīvība; Jānis KloviņšShow moreShow less
1. National Institute of Research and Innovation, Riga, LatviaShow moreShow less
Impact of an integrated monogenic and polygenic risk assessment on Tier-1 conditions in a real-world cohort
Ashley J. Mulford; Zhuqing Shi; Huy Tran; Jun Wei; Annabelle Ashworth; S. Lilly Zheng; Arman Qamar; Karen L. Kaul; Janardan D. Khandekar; Brian T. Helfand; Henry M. Dunnenberger; Peter J. Hulick; Michael S. Caplan; Jianfeng Xu; Alan R. SandersShow moreShow less
1. Genomic Health Initiative, Endeavor Health, Evanston, US; 2. Program for Genomic Translational Research, Endeavor Health, Evanston, US; 3. Cardiovascular Institute, Endeavor Health, Evanston, US; 4. Department of Medicine, Endeavor Health, Evanston, US; 5. Department of Pathology, Endeavor Health, Evanston, US; 6. University of Chicago Pritzker School of Medicine, Chicago, US; 7. Kellogg Cancer Center, Endeavor Health, Evanston, US; 8. Neaman Center for Personalized Medicine, Endeavor Health, Evanston, US; 9. Research Institute, Endeavor Health, Evanston, US; 10. Department of Surgery, Endeavor Health, Evanston, USShow moreShow less
Tumor analysis identifies Israeli founder pathogenic variation carriers
Yael Shiri; Michal Inbar; Ahinoam Gugenheim; Nada Salaymeh; Myriam Maoz; Asher Hilou; Armond Avisrur; Dana Sherill-Rofe; MazalTov Marouani; Yusra Asli; Tamar Peretz; Luna Kadouri; Shiri Shkedi-Rafid; Liza Douiev; Orit Furman; Ruth Perets; Andrew Kelly; Aviad ZickShow moreShow less
1. Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; 2. Sharett Institute for Oncology, Hadassah Medical Center, Faculty of Medicine, The Hebrew University, Jerusalem, Israel; 3. Genetic Department, Hadassah Medical Center, Faculty of Medicine, The Hebrew University, Jerusalem, Israel; 4. Neuro-Oncology Translational Research Lab, Neuro-Radiotherapy Unit and Oncology Institute, Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel; 5. Bruce and Ruth Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; 6. Division of Oncology, and Clinical Research Institute at Rambam, Rambam Health Care Campus, Haifa, Israel; 7. Foundation Medicine, Inc., Boston, USAShow moreShow less
Environmentally responsible human genomic data governance: points for consideration
Narcyz Ghinea; Gabrielle Samuel; Wendy Xin; Emma Bonser; Robert Cook-Deegan; Monica Ferrie; Christopher Gyngell; Margaret Otlowski; Alan Petersen; Bridget Pratt; Susie Roczo-Farkas; Ainsley J. NewsonShow moreShow less
1. Sydney Health Ethics Faculty of Medicine and Health, Sydney School of Public Health, University of Sydney, Sydney, Australia; 2. Department of Global Health and Social Medicine, King’s College London, London, UK; 3. Genetic Alliance Australia, Darlinghurst, Australia; 4. Arizona State University, Washington, USA; 5. Genetic Support Network Victoria, Parkville, Australia; 6. Department of Paediatrics, The University of Melbourne, Melbourne, Australia; 7. Biomedical Ethics, Murdoch Children’s Research Institute, Melbourne, Australia; 8. Melbourne Law School, The University of Melbourne, Parkville, Australia; 9. Faculty of Law, Centre for Law and Genetics, University of Tasmania, Hobart, Australia; 10. School of Social Sciences, Monash University, Clayton, Australia; 11. Queensland Bioethics Centre, Australian Catholic University, Brisbane, Australia; 12. School of Population and Global Health, University of Melbourne, Melbourne, AustraliaShow moreShow less
FAQ
How long does npj Genomic Medicine take to review a manuscript?
As of 2026-11-18, CrushSCI has 15 complete review records for npj Genomic Medicine. The fastest paper went from submission to acceptance in 97 days (Rapid resolution of variants of uncertain significance (VUS). A complementary role for zebrafish in the era of multi-million-dollar therapies, received 2026-04-29, accepted 2026-08-04); the slowest took 328 days. The average is 186.3 days and the median is 165 days.
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
